Pharma BD Deal Intelligence
Oculis buys out its own in-licence, taking full global rights to privosegtor
Full analysis, sources & comparables →Oculis Holding AG signed an asset purchase agreement with Accure Therapeutics S.L. to acquire worldwide rights to privosegtor (ACT-01), Accure's lead neuro-ophthalmology candidate in registrational trials for optic neuropathies and acute multiple sclerosis relapses, at a first closing, and ACT-02, a preclinical neurology candidate, at a subsequent closing contingent on completion of the ACT-01 transaction. Total consideration is an upfront cash payment of USD 3.8 million (CHF 3.1 million) at first closing plus up to 2,050,000 Oculis ordinary shares, comprising locked-up upfront shares and milestone-based earnout shares tied to development and regulatory achievements. The privosegtor closing is expected no later than February 28, 2027, and on completion the existing Oculis-Accure license agreement for privosegtor terminates, eliminating its milestone and royalty obligations.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Oculis Holding AG / Accure Therapeutics S.L. (this deal) | 2026 | $4M | 64 |
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. | 2026 | $2.5B | 75 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd | 2026 | $1.5B | 73 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| Pfizer Inc. / Innovent Biologics, Inc. | 2026 | $10.5B | 71 |
← Browse all deals · How we score deals
More: 2026 deals